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-Glucocerebrosidase (GBA; also referred to as acid 
-glucosidase or GCase; EC 3.2.1.45) is a lysosomal enzyme 
that hydrolyzes glucosylceramides (GlcCers) into cerami-
des (1, 2). Inherited GBA deficiency (as occurs in Gaucher 
disease) results in lysosomal accumulation of GlcCers, pri-
marily in macrophages located in the liver, spleen, and 
bone marrow (3). Complete absence of GBA causes an ex-
treme Gaucher disease phenotype (so-called collodion 
baby) with fatal skin abnormalities (4). Newly synthesized 
GBA is normally transported to the lysosomal compart-
ment by binding to the lysosomal integral membrane pro-
tein type-2 (5). In lysosomes, GBA is active at its optimal 
pH of around 5.2–5.6, assisted by the activator protein, sa-
posin C (6, 7). Besides lysosomal GBA (GBA1), two other 
-glucosidases can be present in cells (GBA2 and GBA3). 
GBA2 can also convert GlcCers into ceramides, implicating 
that such conversion may also occur outside the lysosomes 
(8). Here, GBA1 is used when specifically referring to lyso-
somal -glucosidase, whereas any -glucosidase is indicated 
as GBA.
To date, over 270 GBA mutations have been identified 
(https://research.cchmc.org/LOVD2/) that may either 
lead to reduced protein expression or result in nonfunc-
tional GBA or a reduced enzyme activity (9). GBA expres-
sion levels do not often relate to enzyme activity because of 
various aspects, like posttranslational modifications of the 
protein or cofactors (10). This suggests that GBA activity 
(rather than gene or protein expression) is indicative for 
the clinical outcome. However, current studies on lipid 
metabolic enzymes mainly focus on methods to quantify 
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gene expression or protein levels, rather than enzyme ac-
tivity. To date, enzyme activity is often performed via zy-
mography studies in which a selective substrate is converted 
to a fluorescent product by the enzyme of interest. Many in 
vitro and in situ methods have been established, particularly 
for studies on proteases (11–13). Reports on zymography 
of other enzymes are less common, but GBA is an excellent 
example in which established methods have proven their 
value: 4-methylumbelliferyl--D-glucopyranoside (4-MU--
glc) has been used as a substrate and is converted by GBA 
into the blue fluorophore, 4-methylumbelliferone (em,max ≈ 
450 nm; supplemental Fig. S1) (7). A common alternative 
is resorufin--D-glucopyranoside (res--glc), which results 
in red fluorescent resorufin (em,max ≈ 580 nm). The sub-
strates are limited in their sensitivity and substrate specific-
ity is a matter of concern. Alternatives to zymography are 
therefore needed to examine the presence of active GBA, 
like the use of activity-based probes (ABPs) (14, 15). This 
technique relies on mechanism-based labeling of GBA with 
a fluorescent suicide  inhibitor (16, 17). MDW941 is a cy-
clophellitol -epoxide tagged with a BODIPY red dye (sup-
plemental Fig. S1) (16). It binds covalently to the catalytic 
nucleophile, E340, of GBA1 with high affinity and specific-
ity. Fluorescent ABPs like MDW941 have been successfully 
used to visualize in situ active GBA1 molecules in cultured 
cells and tissues of rodents (16, 18), but human skin tissue 
has so far never been examined with these ABPs.
The aim of this study was to develop, optimize, and com-
pare zymography and ABP-labeling to visualize in situ ac-
tive GBA1 in human skin tissue. Human skin contains a 
dermal and an epidermal component, the latter consisting 
of several layers, including the stratum corneum (SC), the 
nonviable outermost skin layer (Fig. 1). This layer acts as a 
pivotal barrier and contains terminally differentiated enu-
cleated cells embedded in a ceramide-rich lipid matrix 
(19). In this matrix, ceramides are a major component 
and have uniquely long hydrocarbon chains (20). Changes 
in the composition of SC ceramides or the expression of 
GBA1 may lead to an impaired barrier function that has 
been  encountered  in  several  inflammatory  skin  diseases 
(e.g., eczema) (21, 22). These ceramides are synthesized in 
the endoplasmic reticulum of viable epidermal cells (23–
25) and are subsequently stored as GlcCers in vesicles 
(so-called lamellar bodies) together with GBA and other 
enzymes that convert the lipid precursors into barrier lip-
ids (26). This conversion occurs during the lamellar body 
extrusion process: the lamellar bodies fuse with the cell 
membrane and extrude their lipid and enzyme content 
into the extracellular space between the viable epidermis 
and the SC (20). To date, it has been reported that the 
conversion of GlcCers into ceramides by GBA takes place 
in this lipid-rich environment (27, 28). Subsequently, the 
ceramides are arranged into lipid layers (together with other 
barrier lipids, like fatty acids and cholesterol) forming lamel-
lar stacks. These lamellar stacks function as the principal 
barrier and are crucial to protect the body from the environ-
ment (29, 30). The conversion of GlcCers into ceramides 
by GBA1 in the extracellular space is contradictory to the 
notion that GBA1 is solely active in the lysosomal com-
partment (2, 31). Using two newly developed techniques 
(zymography and ABP-labeling), we were able to visualize 
active -glucosidase and, more specifically, active GBA1.
First, the presence of GBA1 from isolated skin layers was 
demonstrated and the specificity of the ABP for GBA1 
(MDW941) in skin lysate was determined. Second, an opti-
mized in situ zymography method was developed, as cur-
rent methods for visualizing GBA activity in skin sections 
have  substantial  (conflicting)  differences  in  their  proce-
dures (7, 32, 33). Third, a new method to detect GBA1 in 
human epidermis by means of in situ ABP-labeling was op-
timized in regard to ABP concentration, buffer conditions, 
and washing procedures. This method was applied on a 
cultured 3D-human skin equivalent (HSE) model that 
mimics human skin (34), while the culture medium was 
supplemented with the GBA1 inhibitor, isofagomine (sup-
plemental Fig. S1). Isofagomine selectively inhibits GBA1 
at low nanomolar concentration, but not the other -
glucosidases, GBA2 and GBA3 (35, 36). This enabled us to 
study whether inhibition of GBA1 activity directly affects 
the SC glucosyl (ceramide) composition.
MATERIALS AND METHODS
Processing human skin
Human skin was processed in accordance with the Declaration 
of Helsinki principles. Skin from mammoplasty or abdomino-
plasty was obtained from local hospitals directly after surgery. Skin 
was dermatomed to a thickness of 400 m after removal of the 
adipose tissue. Skin samples were either processed to culture 
HSEs, used for in vitro GBA analysis, or cryo-frozen for sectioning 
and labeling: small skin samples were put in gelatin capsules filled 
Fig. 1. Epidermis with the outermost layer (SC) fun-
ctioning as the primary skin barrier. The biosynthesis 
of the SC ceramides is located in the lower and middle 
epidermal layers, while storage takes place at the la-
mellar bodies together with processing enzymes like 
GBA. Once extruded at the interface of the viable epi-
dermis and the SC, GBA converts the GlcCers into 
their final barrier components, the ceramides, which 
become part of the ordered SC lipid matrix.
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with matrix specimen Tissue-Tek OCT (Sakura Finetek Europe, 
Alphen a/d Rijn, The Netherlands) and snap-frozen in liquid ni-
trogen. Snap-frozen skin tissue from human skin or HSEs was cut 
to 5 m-thick sections (Leica CM3050s; Leica Microsystems, Ger-
many). Sections were placed on SuperFrost Plus micro slides 
(VWR International, The Netherlands) and used for immunohis-
tochemical stainings or enzyme activity studies (in situ zymogra-
phy and ABP-labeling).
Culturing and harvesting HSEs
HSEs were cultured as described previously (34, 37, 38). Details 
are provided in the supplemental information. Briefly, the epider-
mis was separated from the dermis by Dispase digestion (Roche, 
Almere, The Netherlands). Primary fibroblasts were isolated 
after incubation of the dermis in collagenase (Gibco-Invitrogen, 
Carlsbad, CA) and Dispase II (Roche). Keratinocytes were iso-
lated from the epidermis after trypsin digestion (Sigma-Aldrich, 
Steinheim, Germany). The dermal compartment was cultured 
using isolated rat collagen populated with fibroblasts. Dermal 
equivalents were cultured submerged for 1 week. Then human 
keratinocytes were seeded on the dermal equivalent and the HSEs 
were cultured for 2 days under submerged conditions. The HSEs 
were lifted to the air-liquid interface and cultured for an addi-
tional 2 weeks while supplementing different concentrations of 
the GBA1 inhibitor, isofagomine (0, 0.001, 0.01, 0.1, 0.5, 1, 5, or 
10 M; n  3 for each condition) to the culture medium. Me-
dium was refreshed twice a week. After the culture period, HSEs 
were harvested: HSEs cultured with 0, 0.5, or 5.0 M (isofago-
mine) were snap-frozen (unfixed) and cut in 5 m-thick sections, 
as described above for human skin. These samples were analyzed 
for  in  situ  immunohistochemistry-immunofluorescence  staining 
and ABP-labeling of GBA1. The remaining HSEs were used to 
analyze the SC (glucosyl)ceramides by LC/MS.
In vitro analysis of GBA1 in human skin lysates
From dermatomed skin, the individual skin layers were isolated 
according to the procedures described elsewhere (39, 40): der-
mis, epidermis, SC, and viable skin layers (full thickness skin mi-
nus SC). Dermis was isolated from the epidermis using a 2.4 U/ml 
dispase II solution (Roche). SC was isolated by 0.1% trypsin diges-
tion (Sigma-Aldrich). Human skin was left overnight in 0.1% tryp-
sin in PBS at 4°C. After an incubation period of 1 h at 37°C, the 
SC was isolated and washed once with 0.1% (w/v) trypsin inhibi-
tor in PBS solution and twice in MilliQ. The GBA content was 
determined in various isolated skin layers for: i) the presence of 
GBA1 by Western blotting; ii) the presence of active GBA1 by 
ABP-labeling; and iii) quantitation of GBA1 activity by a 4-MU--
glc assay. All procedures are described briefly below.
Western blot analysis of GBA1. Western blot analysis was per-
formed to examine the presence of GBA1 in human skin. Skin 
lysates were prepared in KPI buffer (25 mM potassium phosphate, 
pH 6.5) and 0.1% (v/v) Triton with cOmplete protease inhibitor 
(Roche) in tubes with 1.0 mm glass beads (BioSpec Products, 
Bartlesville, OK). These tubes were processed on a FastPrep-24 5G 
for 10 cycles of 20 s at a speed of 6 m/s. Samples were filtered on 
a 1 ml disposable spin column (G-Biosciences, St. Louis, MO) and 
spun down for 10 min at 15,000 rpm. The protein concentration 
was quantified by BCA kit (Thermo Scientific, Rockford, IL). Sub-
sequently, lysates were denatured with Laemmli loading buffer 
[312.5 mM Tris-HCl (pH 6.8), 0.1% (w/v) bromophenol blue, 
50% (v/v) glycerol, 10% (w/v) SDS, and 8% (w/v) DTT] and 
heated for 5 min at 98°C. Samples were subjected to 10% SDS-
PAGE and transferred to 0.2 m nitrocellulose membranes by us-
ing a Trans-Blot Turbo system (Bio-Rad). The blots were blocked 
in 5% (w/v) Protifar in PBS 0.1% (v/v) Tween-20 and incubated 
overnight at 4°C with anti-GBA1 monoclonal antibody [8E4 (41)] 
at 1:1,000 dilution in 2% (w/v) Protifar PBS 0.1% (v/v) Tween-20. 
After washing three times in PBST, membranes were incubated 
for 1 h at room temperature with secondary antibody, Alexa Fluor 
647 donkey anti-mouse (Life Technologies, Bleiswijk, The Neth-
erlands), at 1:10,000 dilution in 2% (w/v) Protifar PBS 0.1% (v/v) 
Tween-20. Blots were washed twice in PBST and once in PBS, fol-
lowed by scanning on a Typhoon FLA 9500 scanner (ex = 653 
nm, em = 669 nm). Precision Plus Protein unstained standard 
#1610373 (Bio-Rad) was used as reference ladder.
ABP-labeling of GBA1. To examine whether active GBA1 was 
present in lysates of isolated human skin layers, labeling was per-
formed as described previously (16). Samples were first incubated 
in 100 nM ABP MDW941 in McIlvaine buffer (150 mM citric acid-
Na2HPO4, pH 5.2), 0.2% (w/v) sodium taurocholate, 0.1% (v/v) 
Triton X-100, and 0.1% (w/v) BSA at 37°C for 1 h. Afterwards, 
samples were denatured with Laemmli loading buffer and heated 
for 5 min at 98°C. Gel electrophoresis was performed on 10% 
SDS-polyacrylamide gels, washed afterwards in demineralized wa-
ter and visualized using a Typhoon FLA 9500 scanner, deep red 
(ex = 649 nm, em = 670 nm) and green (ex = 532 nm, em = 554 
nm). Bio-Rad #1610373 was used as reference ladder and no sig-
nificant  autofluorescence  of  the  skin  layers  was  observed  that 
could possibly interfere with the results.
GBA1 activity assay. 4-MU--Glc (Santa Cruz, Dallas, TX) was 
used to measure the GBA activity in the separate skin layers (16). 
Skin lysates were incubated on ice with and without 100 nM 
MDW933 (nonfluorescent GBA1 inhibitor) for 30 min, followed 
by incubation with the 4-MU--Glc mixture at 37°C for 30 min. 
This incubation mixture contained McIlvaine buffer (150 mM 
citric acid-Na2HPO4, pH 5.2), 0.2% (w/v) sodium taurocholate, 
0.1% (v/v) Triton X-100, 0.1% (w/v) BSA, and 3.7 mM 4-MU--
Glc substrate. Afterwards, the substrate reaction was stopped with 
glycine-NaOH (pH 10.3) and the amount of fluorescent product 
(4-methylumbelliferone) was measured with a fluorescence spec-
trometer (LS-55; Perkin Elmer) at ex = 366 nm and em = 445 nm. 
No  significant  autofluorescence  of  the  lysates  was  observed.  By 
subtracting the activity obtained when incubated with GBA1 in-
hibitor from the activity obtained without incubation with inhibi-
tor (nonspecific GBA activity), the actual GBA1 hydrolysis activity 
was determined.
Immunofluorescence staining for GBA1 expression
Skin sections (5 m-thick) were fixed with acetone and washed 
with PBS (pH 7.4). Sections were blocked using 2.5% (v/v) goat 
serum in 1% (v/v) BSA/PBS. Incubation with primary monoclo-
nal GBA1 antibody (ab125065; Abcam, Cambridge, UK) was per-
formed overnight at 4°C. Sections were labeled with secondary 
antibody (Rhodamine Red AffiniPure goat anti-rabbit IgG; Jackson 
ImmunoResearch Laboratories, West Grove, PA). Afterwards, sec-
tions were washed twice in PBS and once in demineralized water 
and subsequently mounted using Vectashield with DAPI solution 
(Vector Laboratories, Burlingame, CA).
In situ zymography of epidermal GBA
Skin sections were washed with 1% (v/v) Tween-20 in MilliQ. 
Afterwards, 1 mM fluorogenic substrate in either 10 mM MES buf-
fer (pH 5.4) or McIlvaine buffer (150 mM citric acid-Na2HPO4, 
pH 5.2) were added to the sections and incubated at 37°C for 
0 min, 10 min, 30 min, 1 h, 2 h, or 16 h. Substrate was either 4-MU-
-glc or res--glc (Marker Gene Technologies, Oregon). For the 
zymography competition assay, an additional preincubation step 
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of 1 h at 37°C with 1 mM isofagomine (Toronto Research Chemi-
cals, Toronto, Canada) was performed. Thereafter, the sections were 
washed briefly with 1% (v/v) Tween-20 solution and subsequently 
either one or three additional washes with MilliQ water. Sections 
were mounted with Vectashield containing either DAPI or prop-
idium iodide for appropriate counterstaining of cell nuclei. The 
main parameters of the optimized protocol are listed in Table 1.
In situ ABP-labeling of active GBA1 in the epidermis
Skin sections were washed with 1% (v/v) Tween-20 (Bio-Rad 
Laboratories) in MilliQ. Afterwards, different concentrations of 
the ABP, MDW941 (10, 100, or 1,000 nM), in either McIlvaine 
buffer or MES buffer were added to the sections and incubated 
for different periods (0, 10, 30, or 60 min) at 37°C. Negative control 
samples were preincubated with a 10 M cyclophellitol-epoxide 
ABP tagged with a nonfluorescent moiety in 150 mM McIlvaine 
buffer [150 mM citric acid-Na2HPO4 (pH 5.2), 0.2% (w/v) sodium 
taurocholate, 0.1% (v/v) Triton X-100]. Thereafter, the samples 
were washed either once or three times in MilliQ water (first wash 
in addition of 1% Tween-20) and mounted using Vectashield with 
DAPI solution. An overview of the final method is provided in 
Table 1.
Fluorescence microscopy
Images were taken using a Zeiss Imager.D2 microscope con-
nected to a Zeiss AxioCam MRm camera (Zeiss, Germany). Im-
ages were taken at objective lens magnifications of 20× and 63× 
(with immersion oil) and with an ocular lens magnification of 
10×. Images were processed using Zen 2 2012, blue edition (Zeiss). 
Exposure times were kept constant for each individual experi-
ment. Gamma was set to 1.0 for all measurements.
SC lipid isolation and (glucosyl)ceramide analysis
SC was isolated from small skin samples by trypsin digestion 
(as described above). Then, lipids were extracted from the SC 
using an extended Bligh and Dyer procedure described by 
Boiten et al. (42) The obtained lipid fraction was reconstituted 
in heptane:chloroform:methanol (95:21/2:21/2) prior to analy-
sis by LC/MS, as explained previously (42). In short, chromatog-
raphy of (glucosyl)ceramides was achieved by an Acquity UPLC 
H-class (Waters, Milford, MA) using gradient elution of heptane 
toward 50% heptane:isopropanol:ethanol (50:25:25) by means 
of a normal phase PVA-silica column (100 × 2.1 mm inner diam-
eter, 5 m particle size; YMC, Kyoto, Japan). A Xevo TQ-S MS, 
equipped with an atmospheric pressure chemical ionization 
source was used for mass analysis in positive-ion full-scan MS 
mode for scanning from m/z 350 to 1,200 amu (ceramides) and 
from m/z 500 to 1,350 amu (GlcCers). Deuterated non-hydroxy 
fatty acid/sphingosine base ceramide (ceramide NS, Evonik In-
dustries, Germany) was used as internal standard. The ratio of the 
areas under the curve of acyl-GlcCers and acyl-ceramides (specifi-
cally ceramide subclasses EOS and EOH, see supplemental Fig. 
S1e, f for the molecular architecture) were subsequently calcu-
lated and will be referred to as GlcCer:ceramide ratio, as reported 
previously (43). We focused specifically on acyl-ceramide sub-
classes because: i) the precursors of these ceramides are solely 
GlcCers and, therefore, only conversion by GBA plays a role in the 
final step of the acyl-ceramide synthesis and results could not be 
obscured by other enzymes (i.e., ceramides that can also be gener-
ated by acid sphingomyelinase); and ii) these ceramides are cru-
cial for a proper SC lipid matrix structure and are therefore 
relevant when studying HSEs in relation to the SC barrier.
RESULTS
GBA1 is primarily located near the interface of the viable 
epidermis and the SC
Isolated lysates of human dermis, epidermis, SC, and the 
viable skin layers minus the SC (full skin-SC) were analyzed 
by Western blotting for the presence of GBA1 protein. 
GBA1 (60 kDa) was expressed more in the epidermis 
than the dermis (Fig. 2A). More specifically, GBA1 was 
predominantly located in the SC, as the viable skin layers 
(skin without SC) showed protein bands with much lower 
intensity. In addition to the Western blot procedure, we 
used the ABP, MDW941, to fluorescently label active GBA1 
in skin tissue (Fig. 2B; fluorescent bands at 60 kDa; Coo-
massie brilliant blue staining for total protein content is 
provided in supplemental Fig. S2). Interestingly, GBA1 lo-
cated in the dermis appears to have a slightly higher mo-
lecular mass compared with GBA1 in the epidermis, which 
matches the presence of two bands in the lysate with epi-
dermis and dermis (full-thickness skin minus SC). Sub-
sequently, a 4-MU--glc activity assay was performed to 
quantify the activity of GBA in the different skin layers (Fig. 
2C). In all skin layers, GBA was shown to be primarily GBA1 
and had the highest activity in epidermal tissue and SC tis-
sue. This is in line with the Western blot and gel electro-
phoresis results presented in Fig. 2A, B, where the most 
pronounced bands were observed in the epidermis and SC 
as well. We then performed in situ immunohistochemical 
staining to determine the exact location of GBA1 expres-
sion (Fig. 2D). In line with the aforementioned results, 
GBA1 proved to be expressed in the viable epidermis and 
SC layers, predominantly along the whole interface of the 
viable epidermis and the SC. Having confirmed that GBA1 
was predominantly expressed and active in epidermal skin 
layers and amenable to selective labeling by MDW941, 
we next established detailed protocols for localizing active 
GBA in human skin tissue. We focused on two in situ 
techniques: i) zymography of GBA, and ii) ABP-labeling 
of GBA1.
TABLE 1. Overview of the optimized in situ protocols to visualize epidermal GBA by zymography and  
ABP-labeling
Parameter In situ Zymography In situ ABP-Labeling
Section fixation Cryo-samples (no fixation) Cryo-samples (no fixation)
[Fluorogenic compound] 1 mM 4-MU--glc or res--glc 100 nM MDW941
Incubation period/temperature 1–2 h, 37°C 1 h, 37°C
Preferred buffer MES MES or McIlvaine
Washing protocol 1× 1% Tween, 3× short rinses in MilliQ 1× 1% Tween, 3× short rinses in MilliQ
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In situ zymography of epidermal GBA: method 
development of 4-MU--glc and res--glc substrates
We optimized the zymography protocol for two com-
monly used substrates, 4-MU--glc and res--glc, which, 
upon conversion by GBA,  lead  to  their fluorescent prod-
ucts, 4-methylumbelliferone (indigo) and resorufin (or-
ange/red). The procedure to obtain the high resolution in 
situ zymography images was an important aspect of the op-
timization procedure. We optimized the protocol for the 
following four important aspects concerning substrate re-
constitution, washing procedure, substrate incubation buf-
fer, and incubation period and temperature. First, res--glc 
is relatively insoluble in buffer solution, leading to fluores-
cent clusters that interfere with imaging. Dissolving the 
substrate in dimethylsulfoxide (i.e., 1 mM) prior to dilution 
in buffer completely removed this. The 4-MU--glc could 
be dissolved directly in buffer, without any additional steps. 
Second, after incubation with substrate, washing is neces-
sary to successfully remove background staining. Three short 
rinses with MilliQ water (the first one in addition with 
Tween-20) resulted in the best contrast between fluorescent 
signal and aspecific staining. Longer or more wash steps 
resulted  in  significant  loss  of  fluorescent  signal,  whereas 
less washing led to reduced contrast (see supplemental Fig. 
S3). Third, we incubated the samples with two commonly 
used substrate buffers for zymography, 10 mM MES solu-
tion and 150 mM McIlvaine solution. Fourth, the effect of 
incubation period and temperature was investigated, using 
an incubation period between 0 and 16 h at 4°C or 37°C.
The results on the optimized protocol are depicted in 
Fig. 3 (and supplemental Fig. S4). Both substrates visualized 
GBA in skin sections and provided similar results: fluores-
cent product was observed at the viable epidermis-SC 
interface of human skin sections (Fig. 3A). To exclude 
nonspecific staining, we performed a competition assay in 
which we preincubated skin sections with a commonly 
used competitive GBA1-specific inhibitor, isofagomine. 
Consecutive incubation with substrate res--glc (in addi-
tion to equimolar concentrations of isofagomine to main-
tain competition) resulted in no significant staining (Fig. 
3B), indicating that isofagomine successfully inhibited 
GBA1 activity and that the substrates were indeed con-
verted by GBA1. Without any substrate (negative control), 
no staining was observed either (Fig. 3C). When studying 
the catalytic conversion of substrate by GBA at higher mag-
nification levels (e.g., 63×), “layers” of fluorescent product 
were formed, as can be seen from Fig. 3D and the zoomed 
section. The presence of GBA activity in the intercellular 
SC regions was also clearly visualized when using 4-MU--
glc as substrate (Fig. 3E). Incubation for at least 1 h at 37°C 
did result in sufficient fluorescent signal at the viable epi-
dermis-SC interface. It was determined that longer incuba-
tion periods (e.g., 16 h) should be avoided to prevent 
excessive diffusion of fluorescent product throughout the 
section, even at the reduced temperature of 4°C (Fig. 3F).
Developing an in situ ABP-labeling procedure for 
localizing active GBA1 in the epidermis
We established a new method for visualizing active GBA1 
in human epidermal skin tissue by means of ABP-labeling. 
We optimized the method for ABP concentration, incuba-
tion period, buffer type, and washing procedure. Concern-
ing ABP concentration, labeling was already successful at 
10 nM MDW941; however, more robust and high contrast 
staining was obtained at 100 nM concentrations. Higher 
concentrations (e.g., 1 M) did not result in more intense 
staining, but increased the risk of nonspecific labeling 
(precipitation of the probe) (see supplemental Fig. S5). 
Fig. 2. Labeling of GBA1 in human skin tissue. A: 
Western blot of GBA1 in different human skin tissue 
layers using monoclonal anti-GBA1 (50 g of protein 
per lane were loaded on the SDS-PAGE gel). Full skin-
SC, full thickness skin without SC. B: Fluorescent la-
beling of active GBA1 (5 g of protein per lane were 
loaded on the SDS-PAGE gel) in skin tissues exposed 
to MDW941. C: Bar plots of the enzymatic activity of 
GBA in skin tissue, as determined by a 4-MU--glc 
substrate assay (gray + black bars). The fraction of 
4-methylumbelliferone converted by GBA1 is indi-
cated by black bars (n = 3, mean ± SD). D: Immunohis-
tochemical  fluorescent  staining  of  expressed  GBA1 
(red), and counterstaining with DAPI (blue) for cell 
nuclei. Objective lens magnification 20×.
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When optimizing incubation period, we demonstrated that 
labeling was already observable after 30 min of incubation, 
but an 1 h incubation period proved optimal (Fig. 4A). 
At 63× objective lens magnification, it became apparent 
that GBA1 was present not only at the viable epidermis-SC 
interface but also in the lower SC layers, as fluorescent lay-
ers of ABP-labeling appeared (Fig. 4B), similar to the fluo-
rescent layers observed with the zymography method. To 
exclude that MDW941 labels at nonspecific sites of the skin 
sections, we preincubated sections in excess of a nonfluo-
rescent selective GBA1 probe (44, 45). This nonfluorescent 
probe binds covalently to E340 of GBA1 only. Its irrevers-
ible binding prohibits binding of MDW941 in the subse-
quent incubation period. Indeed, Fig. 4C demonstrated no 
Fig. 3. GBA in situ zymography assay on human skin sections. A: Microscopy photographs of 20× magnification using res--glc substrate 
(red) and DAPI counterstaining to detect cell nuclei (blue). B: Additional preincubation with competitive GBA inhibitor, resorufin, success-
fully obstructs substrate conversion. C: No red fluorescence is observed when no substrate is applied (negative control). D: Photograph (63× 
magnification) in which the red fluorescent product layers are indicated by the white arrows. E: Images (63× magnification) using 4-MU--
glc substrate focusing on the blue fluorescent product layers. Red counterstaining was performed using propidium iodide to stain cell nuclei. 
F: Microscopy images (63× magnification) of the results from different substrate incubation periods (0, 1, and 16 h). White arrows indicate 
highest signal contrast, whereas black arrows illustrate the diffusion effect of the fluorescent product at longer time periods. Scale bars rep-
resent 20 m.
Fig. 4. In situ GBA labeling by MDW941 ABP. Microscope images (63× magnification) of human skin sections incubated with the ABP, 
MDW941 (yellow/orange), and counterstained with DAPI (blue). Scale bar represents 20 m unless stated otherwise. A: Incubation period assay 
of 10, 30, and 60 min incubation periods. At 10 min, some weak ABP-labeling is already present (white arrow). B: When zooming in on the viable 
epidermis-SC interface, prominent labeling of active GBA1 is observed. C: Competition assay of ABPs in which human skin sections were prein-
cubated with nonfluorescent ABP (cylophellitol-epoxide tagged with a nonfluorescent moiety) prior to incubation with MDW941. The 
dotted line indicates the outermost SC layer. D: Human skin sections incubated without any ABP (negative control). E: High magnification of 
the viable epidermis-SC interface at skin sections in which the SC was not flattened, illustrating MDW941 labeling around the corneocytes 
(DAPI-counterstaining of nuclei in the viable epidermis is not visualized for better visualization of GBA1 in the extracellular lipid matrix).
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visible fluorescent  signal  (thus no MDW941 binding),  il-
lustrating specific labeling of active GBA1 by MDW941 in 
human skin sections. No background staining was observed, 
as incubation without ABP (negative control samples) re-
sulted in no detectable staining (Fig. 4D). MDW941 label-
ing on skin that was not fully differentiated (and thus shows 
no  full flattening of  the corneocytes  in  the SC)  revealed 
that the ABP was located in the lipid matrix surrounding the 
corneocytes (Fig. 4E). Note that when optimizing buffer, 
we obtained identical results when using MES and McIlvaine 
buffer; therefore, both buffers are considered suitable for 
ABP-labeling. Regarding washing procedure, we observed 
that washing at least three times proved superior over wash-
ing once, as the latter procedure did not always remove all 
unlabeled MDW941. The newly developed GBA1 ABP- 
labeling proved quick and very reproducible, resulting in 
high resolution imaging, even at low concentrations of 
MDW941. This method was therefore used to study GBA1 
expression in HSEs in which GBA1 activity was modulated.
Altered GBA1 activity in HSEs cultured with isofagomine
We applied our optimized in situ ABP method to a HSE 
that resembles, to a large extent, the morphology and lipid 
composition in human skin. During generation of these 
HSEs, the medium was supplemented with 0–100 M 
isofagomine, a potent reversible GBA1 inhibitor. We ana-
lyzed to what extent GBA1 expression and activity were af-
fected by isofagomine in culture medium. Figure 5A shows 
that GBA1 in HSEs (as visualized with a specific antibody) 
was mainly located at the viable epidermis-SC interface, 
similar to the observations made for human skin (Fig. 2D). 
This expression at the viable epidermis-SC interface was 
not decreased when cultured with 0.5 or 5 M isofagomine 
in the medium. In fact, GBA1 expression was observed 
throughout all SC layers. Besides, adding isofagomine to 
the culture medium resulted in more GBA1 staining near 
the nuclei of viable epidermal cells (see arrows in Fig. 5A), 
which implied an increase in de novo GBA1 expression 
and thus GBA1 synthesis. When analyzing the presence of 
active GBA1 using the ABP, MDW941, in the absence of 
isofagomine, labeling was observed at the viable epidermis-
SC interface and the lower SC layers (Fig. 5B), in line with 
the expression pattern observed in Fig. 5A. Interestingly, 
labeling of active GBA1 at the viable epidermis-SC inter-
face was lost when inhibitor (0.5 and 5 M) isofagomine 
was added to the medium. Only a weak staining at the out-
ermost SC layers remained.
SC ceramides in HSEs are altered when cultured with 
isofagomine
Because we observed changes in GBA1 in HSEs cultured 
with the inhibitor, isofagomine, we analyzed the SC cerami-
des of these HSEs by means of LC/MS. Figure 6 depicts 
the GlcCer:ceramide ratios of two acylceramide subclasses, 
EOS and EOH, respectively. At 1 nM isofagomine concen-
tration (far below the Ki,isofagomine of 20 nM) (46), a ratio 
around 0.8 was observed, indicating that 7% of ceramide 
EOS remained glycosylated at this culturing condition. 
When the isofagomine concentration was increased, the 
GlcCer:ceramide ratio was also increased for both ce-
ramide EOS and EOH. At concentrations of 10 M isofago-
mine, the ratio increased significantly to 0.35 ± 0.06 and 
0.42 ± 0.20 for EOS and EOH, respectively. This indicated 
that the conversion of GlcCers into ceramides was success-
fully hampered by the competitive inhibitor, isofagomine. 
The HSE model can therefore be supplemented with spe-
cific concentrations to modulate the exact amount of 
GlcCers:ceramides.
DISCUSSION
This study first reported on the presence of active GBA1 
in human skin, which was primarily located outside the ly-
sosomes in the extracellular space of the inner layers of 
the lipophilic SC lipid matrix. GBA1 activity in such an 
Fig. 5.  A:  Immunohistochemical  fluorescent  staining  of  ex-
pressed GBA1 (red) in HSEs cultured with isofagomine or without 
(control). DAPI was used for counterstaining, indicating blue-la-
beled cell nuclei. White arrows point to GBA labeling near the nu-
clei of viable keratinocytes. B: In situ visualization of active GBA 
labeled with MDW941 in HSEs cultured with isofagomine. Yellow/
orange staining (MDW941) indicates active GBA1. Blue indicates 
cell nuclei (DAPI). All images were taken at a 63× magnification. 
Scale bar represents 20 m. The dotted line indicates the viable 
epidermis-SC interface.
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environment is unique and has hitherto not been observed 
in any other tissues. We described two independent meth-
ods to visualize the presence of active GBA1 in the extracel-
lular space: zymography and ABP-labeling. Although the 
presence of GBA at the viable epidermis-SC interface has 
been reported before using zymography (7, 32, 33, 47–49), 
the specificity of the substrates (res--glc and 4-MU--glc) 
has been debated, as both are converted by several -
glucosidases (50–52). Therefore, we developed a new method 
that uses the ABP, MDW941. This aziridine-based probe 
has unmatched sensitivity and specificity toward lysosomal 
GBA1 and delivers superior spatial resolution images. Be-
low, we discuss and compare both methods (summarized 
in Table 1).
Zymography
The developed procedure is compatible with the two 
most commonly used substrates in relation to GBA activity. 
The method is robust, less time-consuming, and provides 
higher resolution images than most reported protocols. 
The following optimization steps proved crucial for the im-
proved results, and are related to sample preparation, incu-
bation period, choice of substrate, incubation buffer, and 
washing procedures.
First, reported in situ methods sometimes use fixation 
solvents to localize GBA activity (7, 32), but this mitigates 
GBA activity and should be avoided (53–55). Cryo-fixed 
sections without fixation solvent on SuperFrost glass slides 
are therefore preferred.
Second, the optimal incubation period with 4-MU--glc 
or res--glc was around 1–2 h. Shorter incubation periods 
led to significantly less fluorescent product, whereas longer 
incubation periods caused diffusion of  the fluorescent 
product. Takagi et al. (7) proposed an incubation period 
of 16 h at the reduced temperature of 4°C to minimize dif-
fusion of product, but our proposed method demonstrated 
clearer contrast of converted product when applying an 
incubation period of less than 2 h at 37°C. Besides, incuba-
tion at 37°C more closely resembles the in vivo situation 
and, thus, the physiological activity of GBA.
Third, no significant difference was observed between 
the two substrates, res--glc (orange/red) and 4-MU--glc 
(indigo), for in situ visualization of active GBA. Neither 
substrate showed significant overlap in its emission wave-
length with its respective counterstain (DAPI and propid-
ium iodide). Green fluorophores were avoided because of 
the autofluorescence of skin tissue caused by components 
like collagen, elastin, melanin, and keratin (56, 57). We did 
not observe  any  emitted fluorescence  signal  for  res--glc 
at the excitation and emission wavelengths proposed by 
Hachem et al. (33) (588 and 644 nm, respectively).
Fourth, GBA1 activity is optimal around pH 5.2–5.6 (6, 
7). The use of appropriate buffers is therefore crucial and 
preferred over the use of deionized water as the substrate 
solvent, as has been used in other protocols (33). MES buf-
fer (10 mM) was preferred over 150 mM McIlvaine buffer, 
as the images were more consistent and more often re-
sulted in clear “layered” patterns of converted fluorescent 
product in the SC. This could be related to the high salt 
concentration of McIlvaine buffer, which may affect the 
surface charge and tertiary structure of GBA, leading to 
changes in enzyme activity (58).
Fifth, we noticed significantly better results after opti-
mizing the washing steps. Directly after cryo-sectioning, 
protocols should include a washing procedure to remove 
specimen matrix (e.g., Tissue-Tek). In agreement with 
Man et al. (59), we observed that the matrix was easily re-
moved when washing with 1% Tween-20 in water. A second 
washing step was introduced directly after the substrate in-
cubation step. A dip-wash with deionized water that was re-
peated three times appeared to be optimal; the first wash 
was with the addition of 1% Tween-20.
ABP-labeling
ABP-labeling has several advantages compared with the 
zymography procedure: i) MDW941 labeling proved much 
more sensitive, as incubation with 100 nM ABP was suffi-
cient for proper localization, whereas 1 mM substrate was 
preferred for zymography. ii) MDW941 is GBA1 specific, in 
contrast to 4-MU--glc and res--glc, which are ligands for 
all -glucosidase subtypes (GBA1–3). Hence, only the ABP-
labeling method demonstrated that visualized protein is 
indeed lysosomal GBA1. iii) Covalent binding of ABP was 
less dependent on incubation period and washing proce-
dures, and labeling with the ABP, MDW941, does not require 
enzyme-based protonation (thus incubation near optimal 
pH) (44). iv) Generally, reproducibility of in situ zymogra-
phy is a main concern and repeated measurements are 
necessary to compensate for irregular results (60). In con-
trast, ABP-labeling delivers more robust images of active 
GBA1 along the entire skin section. As a consequence, ABP-
labeling requires a significantly lower number of skin sec-
tions for reliable conclusions in comparison to zymography.
Recapitulating, this is the first time that the highly sensi-
tive and selective MDW941 label demonstrates that active 
GBA1 is located in the lipophilic extracellular matrix outside 
Fig. 6. GlcCer:ceramide ratios of ceramide (CER) 
subclasses EOS and EOH in HSEs cultured with dif-
ferent concentrations isofagomine. Bar plots depict 
mean ± SD from three independent donor experi-
ments with at least two or more cultures per experi-
ment. As a control, a pool of >10 human SC samples 
was analyzed (HSC condition).
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the lysosomes of human skin, which is unique with respect 
to both environmental condition and localization as ob-
served in cells of other tissues (16, 18). ABP sensitivity also 
becomes apparent when comparing ABP-labeling to the 
in vitro Western blotting procedure: for successful visual-
ization of GBA1, only 5 g of protein was loaded for the 
ABP-labeling procedure, whereas 50 g was required for 
the Western blot procedure. ABP-labeling of skin lysates 
demonstrated that active GBA1 in the dermis is of differ-
ent molecular size than active GBA1 in the epidermis. This 
suggests that different isoforms are present in both skin 
layers, consistent with our finding that N-glycanase treat-
ment converted both dermal and epidermal GBA1 to an 
identical molecular weight (61–63). In the dermis, GBA1 is 
likely located in the lysosomes of cells (fibroblasts, macro-
phages, and adipocytes), where it degrades GlcCer as the 
penultimate step in cellular glycosphingolipid turnover.
The unmatched sensitivity of ABP-labeling proved useful 
when studying HSEs. GBA1 expression and activity in HSEs 
is localized at the same epidermal layers compared with hu-
man skin. Supplementation of isofagomine, a commonly 
used potent reversible inhibitor of GBA1 (52, 64, 65), to 
the medium demonstrated that the activity of GBA1 can be 
altered without significantly reducing GBA1 expression or 
inducing any morphological effects. Localization of active 
GBA1 in the epidermis is therefore essential for under-
standing the consequences of the SC ceramide composi-
tion. Inhibition of GBA1 by isofagomine resulted in a 
concentration-dependent increase of the precursors, acyl-
GlcCer EOS and acyl-GlcCer EOH, compared with their 
acyl-ceramide products. We specifically studied these two 
ceramide subclasses, as it is known that ceramides EOS and 
EOH are not substrates for a second enzyme (acid sphingo-
myelinase) that converts sphingomyelins into ceramides 
(66). A high concentration of isofagomine in the medium 
led to complete inhibition of GBA1 at the viable epidermis-
SC interface and only a weak ABP-labeling in the outer SC 
layers was observed. This indicates that isofagomine reaches 
the SC layers and proves that GBA1 activity is crucial for the 
SC ceramide composition. We explain GBA1 activity in the 
outer SC layers by the fact that isofagomine may not suffi-
ciently diffuse into the upper SC layers and inhibit GBA1. 
Besides, competition between substrates, endogenous GBA1, 
and isofagomine still occurs, as isofagomine is a revers-
ible inhibitor and the medium is refreshed twice a week. 
Any remaining GBA1 activity is therefore expected to be at 
the lowest isofagomine concentration, i.e., the outermost 
SC layers. Nevertheless, the concentration-dependent ef-
fect indicates that the conversion by GBA1 can be modu-
lated by hampering enzyme activity, irrespective of GBA1 
expression. This supplement may therefore be useful to 
target GBA1 to model skin barrier dysfunction related to 
specific diseases. Gaucher disease is an obvious candidate, 
but a dysfunction in GBA1 expression is also observed in 
skin disorders like Netherton syndrome and atopic derma-
titis (21, 43). The significance of GBA1 activity in these skin 
diseases remains inconclusive (67–69) and the presented 
methods here will be used in future studies to unravel this 
aspect, along with the relationship to environmental factors, 
like skin hydration and the SC pH gradient. We observed 
active GBA1 primarily in the innermost SC layers, which 
may be related to the slightly acidic pH gradient across the 
SC. The pH of the inner SC layers (5–6) is at the optimal 
pH of GBA1 (70). This acidic pH may aid GBA1 activity in 
the extracellular SC environment, even at the outermost 
SC layers that are extremely lipophilic. In relation to Neth-
erton syndrome and atopic dermatitis, changes in environ-
mental factors, like SC humidity and pH gradient, have 
been reported as possible causes for changes in GBA1 activ-
ity (33, 47, 70–72). GBA1 has been reported as a key media-
tor for skin barrier homeostasis, as changes in epidermal 
GBA1-activity have been observed in cases of skin barrier 
disruption (73).
In conclusion, we provided two independent methods 
to visualize epidermal GBA and demonstrated that, in both 
human skin and our HSEs, active GBA1 was predominantly 
present in the extracellular space of the SC lipid matrix. 
ABP-labeling demonstrated changes in GBA1 activity for 
HSEs cultured with inhibitor, explaining the altered SC 
(glucosyl)ceramide composition in these HSEs. In combi-
nation with immunohistochemical staining for the expres-
sion of GBA1 and the use of MS to quantify endogenous 
GlcCers and ceramides, these methods that visualize active 
GBA1 bridge the gap between analysis on protein expres-
sion level and the final phenotype, the SC ceramide profile. 
ABP-labeling is superior to zymography in terms of sensitiv-
ity, specificity, and robustness, and the ABP, MDW941, is 
compatible with skin of human and murine origin (16, 44). 
ABP-labeling may therefore be used in future studies to ad-
dress GBA1 activity in relation to skin barrier diseases.
The authors thank Evonik Industries (Essen, Germany) for 
providing deuterated ceramide NS to quantify LC/MS data.
REFERENCES
 1. Holleran, W. M., Y. Takagi, and Y. Uchida. 2006. Epidermal sphin-
golipids: metabolism, function, and roles in skin disorders. FEBS 
Lett. 580: 5456–5466.
 2. Wennekes, T., R. J. van den Berg, R. G. Boot, G. A. van der Marel, 
H. S. Overkleeft, and J. M. Aerts. 2009. Glycosphingolipids–nature, 
function, and pharmacological modulation. Angew. Chem. Int. Ed. 
Engl. 48: 8848–8869.
 3. Rosenbloom, B. E., and N. J. Weinreb. 2013. Gaucher disease: a 
comprehensive review. Crit. Rev. Oncog. 18: 163–175.
 4. Stone, D. L., W. F. Carey, J. Christodoulou, D. Sillence, P. Nelson, 
M. Callahan, N. Tayebi, and E. Sidransky. 2000. Type 2 Gaucher dis-
ease: the collodion baby phenotype revisited. Arch. Dis. Child. Fetal 
Neonatal Ed. 82: F163–F166.
 5. Reczek, D., M. Schwake, J. Schröder, H. Hughes, J. Blanz, X. Jin, W. 
Brondyk, S. Van Patten, T. Edmunds, and P. Saftig. 2007. LIMP-2 is 
a receptor for lysosomal mannose-6-phosphate-independent target-
ing of beta-glucocerebrosidase. Cell. 131: 770–783.
 6. Vaccaro, A. M., M. Muscillo, and K. Suzuki. 1985. Characterization 
of human glucosylsphingosine glucosyl hydrolase and comparison 
with glucosylceramidase. Eur. J. Biochem. 146: 315–321.
 7. Takagi, Y., E. Kriehuber, G. Imokawa, P. M. Elias, and W. M. 
Holleran. 1999. Beta-glucocerebrosidase activity in mammalian stra-
tum corneum. J. Lipid Res. 40: 861–869.
 8. van Weely, S., M. Brandsma, A. Strijland, J. M. Tager, and J. M. Aerts. 
1993. Demonstration of the existence of a second, non-lysosomal 
glucocerebrosidase that is not deficient in Gaucher disease. Biochim. 
Biophys. Acta. 1181: 55–62.
 at W
alaeus Library / BIN 299, on January 9, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2017/10/12/jlr.M079376.DC1
Supplemental Material can be found at:
2308 Journal of Lipid Research Volume 58, 2017
 9. Horowitz, M., and A. Zimran. 1994. Mutations causing Gaucher dis-
ease. Hum. Mutat. 3: 1–11.
 10. Ryšlavá, H., V. Doubnerová, D. Kavan, and O. Vaněk. 2013. Effect of 
posttranslational modifications on enzyme function and assembly. J. 
Proteomics. 92: 80–109.
 11. Wilkesman, J., and L. Kurz. 2009. Protease analysis by zymography: a 
review on techniques and patents. Recent Pat. Biotechnol. 3: 175–184.
 12. Vandooren, J., N. Geurts, E. Martens, P. E. Van den Steen, and G. 
Opdenakker. 2013. Zymography methods for visualizing hydrolytic 
enzymes. Nat. Methods. 10: 211–220.
 13. George, S. J., and J. L. Johnson. 2010. In situ zymography. Methods 
Mol. Biol. 622: 271–277.
 14. Cravatt, B. F., A. T. Wright, and J. W. Kozarich. 2008. Activity-based 
protein profiling: from enzyme chemistry to proteomic chemistry. 
Annu. Rev. Biochem. 77: 383–414.
 15. Willems, L. I., H. S. Overkleeft, and S. I. van Kasteren. 2014. Current 
developments in activity-based protein profiling. Bioconjug. Chem. 
25: 1181–1191.
 16. Witte, M. D., W. W. Kallemeijn, J. Aten, K. Y. Li, A. Strijland, W. E. 
Donker-Koopman, A. M. van den Nieuwendijk, B. Bleijlevens, G. 
Kramer, B. I. Florea, et al. 2010. Ultrasensitive in situ visualization of 
active glucocerebrosidase molecules. Nat. Chem. Biol. 6: 907–913.
 17. Witte, M. D., G. A. van der Marel, J. M. F. G. Aerts, and H. S. Overkleeft. 
2011. Irreversible inhibitors and activity-based probes as research 
tools in chemical glycobiology. Org. Biomol. Chem. 9: 5908–5926.
 18. Herrera Moro Chao, D., W. W. Kallemeijn, A. R. Marques, M. Orre, 
R. Ottenhoff, C. van Roomen, E. Foppen, M. C. Renner, M. Moeton, 
M. van Eijk, et al. 2015. Visualization of active glucocerebrosidase in 
rodent brain with high spatial resolution following in situ labeling 
with fluorescent activity based probes. PLoS One. 10: e0138107.
 19. Elias, P. M. 1983. Epidermal lipids, barrier function, and desquama-
tion. J. Invest. Dermatol. 80 (Suppl.): 44s–49s.
 20. Feingold, K. R., and P. M. Elias. 2014. Role of lipids in the formation 
and maintenance of the cutaneous permeability barrier. Biochim. 
Biophys. Acta. 1841: 280–294.
 21. van Smeden, J., M. Janssens, G. S. Gooris, and J. A. Bouwstra. 2014. 
The important role of stratum corneum lipids for the cutaneous 
barrier function. Biochim. Biophys. Acta. 1841: 295–313.
 22. Ishikawa, J., H. Narita, N. Kondo, M. Hotta, Y. Takagi, Y. Masukawa, 
T. Kitahara, Y. Takema, S. Koyano, S. Yamazaki, et al. 2010. Changes 
in the ceramide profile of atopic dermatitis patients. J. Invest. 
Dermatol. 130: 2511–2514.
 23. Pewzner-Jung, Y., S. Ben-Dor, and A. H. Futerman. 2006. When 
do lasses (longevity assurance genes) become CerS (ceramide syn-
thases)? Insights into the regulation of ceramide synthesis. J. Biol. 
Chem. 281: 25001–25005.
 24. Rabionet, M., K. Gorgas, and R. Sandhoff. 2014. Ceramide synthesis 
in the epidermis. Biochim. Biophys. Acta. 1841: 422–434.
 25. Lampe, M. A., M. L. Williams, and P. M. Elias. 1983. Human epider-
mal lipids: characterization and modulations during differentiation. 
J. Lipid Res. 24: 131–140.
 26. Fartasch, M. 2005. The epidermal lamellar body as a multifunctional 
secretory organelle. In Skin Barrier. P. M. Elias and K. R. Feingold, 
editors. CRC Press, Boca Raton, FL. 261–272.
 27. Hamanaka, S., M. Hara, H. Nishio, F. Otsuka, A. Suzuki, and Y. 
Uchida. 2002. Human epidermal glucosylceramides are major precur-
sors of stratum corneum ceramides. J. Invest. Dermatol. 119: 416–423.
 28. Hannun, Y. A., and L. M. Obeid. 2008. Principles of bioactive lipid 
signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9: 
139–150.
 29. Groen, D., D. S. Poole, G. S. Gooris, and J. A. Bouwstra. 2011. Is an 
orthorhombic lateral packing and a proper lamellar organization 
important for the skin barrier function? Biochim. Biophys. Acta. 1808: 
1529–1537.
 30. Bouwstra, J., G. Gooris, and M. Ponec. 2002. The lipid organisation 
of the skin barrier: liquid and crystalline domains coexist in lamellar 
phases. J. Biol. Phys. 28: 211–223.
 31. Cooper, G. M., and R. E. Hausman. 2016. The Cell: A Molecular 
Approach. 7th edition. Sinauer Associates, Inc., Sunderland, MA.
 32. Schmuth, M., K. Schoonjans, Q. C. Yu, J. W. Fluhr, D. Crumrine, J. 
P. Hachem, P. Lau, J. Auwerx, P. M. Elias, and K. R. Feingold. 2002. 
Role of peroxisome proliferator-activated receptor alpha in epider-
mal development in utero. J. Invest. Dermatol. 119: 1298–1303.
 33. Hachem, J. P., D. Crumrine, J. Fluhr, B. E. Brown, K. R. Feingold, 
and P. M. Elias. 2003. pH directly regulates epidermal permeability 
barrier homeostasis, and stratum corneum integrity/cohesion. J. 
Invest. Dermatol. 121: 345–353.
 34. Thakoersing, V. S., G. S. Gooris, A. Mulder, M. Rietveld, A. El 
Ghalbzouri, and J. A. Bouwstra. 2012. Unraveling barrier properties 
of three different in-house human skin equivalents. Tissue Eng. Part 
C Methods. 18: 1–11.
 35. Berger, Z., S. Perkins, C. Ambroise, C. Oborski, M. Calabrese, S. 
Noell, D. Riddell, and W. D. Hirst. 2015. Tool compounds robustly 
increase turnover of an artificial substrate by glucocerebrosidase in 
human brain lysates. PLoS One. 10: e0119141.
 36. Dulsat, C., and N. Mealy. 2009. Isofagomine tartrate. Drugs Future. 
34: 23.
 37. El Ghalbzouri, A., S. Commandeur, M. H. Rietveld, A. A. Mulder, 
and R. Willemze. 2009. Replacement of animal-derived collagen 
matrix by human fibroblast-derived dermal matrix for human skin 
equivalent products. Biomaterials. 30: 71–78.
 38. Ponec, M., A. Weerheim, J. Kempenaar, A. Mulder, G. S. Gooris, J. 
Bouwstra, and A. M. Mommaas. 1997. The formation of competent 
barrier lipids in reconstructed human epidermis requires the pres-
ence of vitamin C. J. Invest. Dermatol. 109: 348–355.
 39. Nugroho, A. K., L. Li, D. Dijkstra, H. Wikstrom, M. Danhof, and 
J. A. Bouwstra. 2005. Transdermal iontophoresis of the dopamine 
agonist 5-OH-DPAT in human skin in vitro. J. Control. Release. 103: 
393–403.
 40. Haisma, E. M., M. H. Rietveld, A. de Breij, J. T. van Dissel, A. El 
Ghalbzouri, and P. H. Nibbering. 2013. Inflammatory and antimi-
crobial responses to methicillin-resistant Staphylococcus aureus in 
an in vitro wound infection model. PLoS One. 8: e82800.
 41. Aerts, J. M., W. E. Donker-Koopman, G. J. Murray, J. A. Barranger, J. 
M. Tager, and A. W. Schram. 1986. A procedure for the rapid purifi-
cation in high yield of human glucocerebrosidase using immunoaf-
finity chromatography with monoclonal antibodies. Anal. Biochem. 
154: 655–663.
 42. Boiten, W., S. Absalah, R. Vreeken, J. Bouwstra, and J. van Smeden. 
2016. Quantitative analysis of ceramides using a novel lipidomics 
approach with three dimensional response modelling. Biochim. 
Biophys. Acta. 1861: 1652–1661.
 43. van Smeden, J., M. Janssens, W. A. Boiten, V. van Drongelen, L. 
Furio, R. J. Vreeken, A. Hovnanian, and J. A. Bouwstra. 2014. 
Intercellular skin barrier lipid composition and organization in 
Netherton syndrome patients. J. Invest. Dermatol. 134: 1238–1245.
 44. Kallemeijn, W. W., K. Y. Li, M. D. Witte, A. R. Marques, J. Aten, 
S. Scheij, J. Jiang, L. I. Willems, T. M. Voorn-Brouwer, C. P. van 
Roomen, et al. 2012. Novel activity-based probes for broad-spec-
trum profiling of retaining beta-exoglucosidases in situ and in vivo. 
Angew. Chem. Int. Ed. Engl. 51: 12529–12533.
 45. Chandrasekar, B., T. Colby, A. Emran Khan Emon, J. Jiang, T. N. 
Hong, J. G. Villamor, A. Harzen, H. S. Overkleeft, and R. A. van der 
Hoorn. 2014. Broad-range glycosidase activity profiling. Mol. Cell. 
Proteomics. 13: 2787–2800.
 46. Kuriyama, C., O. Kamiyama, K. Ikeda, F. Sanae, A. Kato, I. Adachi, 
T. Imahori, H. Takahata, T. Okamoto, and N. Asano. 2008. In vi-
tro inhibition of glycogen-degrading enzymes and glycosidases by 
six-membered sugar mimics and their evaluation in cell cultures. 
Bioorg. Med. Chem. 16: 7330–7336.
 47. Hatano, Y., M. Q. Man, Y. Uchida, D. Crumrine, T. C. Scharschmidt, 
E. G. Kim, T. M. Mauro, K. R. Feingold, P. M. Elias, and W. M. 
Holleran. 2009. Maintenance of an acidic stratum corneum pre-
vents emergence of murine atopic dermatitis. J. Invest. Dermatol. 129: 
1824–1835.
 48. Ilic, D., M. Mao-Qiang, D. Crumrine, G. Dolganov, N. Larocque, 
P. Xu, M. Demerjian, B. E. Brown, S. T. Lim, V. Ossovskaya, et al. 
2007. Focal adhesion kinase controls pH-dependent epidermal bar-
rier homeostasis by regulating actin-directed Na+/H+ exchanger 1 
plasma membrane localization. Am. J. Pathol. 170: 2055–2067.
 49. Hachem, J. P., T. Roelandt, N. Schurer, X. Pu, J. Fluhr, C. Giddelo, 
M. Q. Man, D. Crumrine, D. Roseeuw, K. R. Feingold, et al. 2010. 
Acute acidification of stratum corneum membrane domains using 
polyhydroxyl acids improves lipid processing and inhibits degrada-
tion of corneodesmosomes. J. Invest. Dermatol. 130: 500–510.
 50. Ben-Yoseph, Y., and H. L. Nadler. 1978. Pitfalls in the use of artificial 
substrates for the diagnosis of Gaucher’s disease. J. Clin. Pathol. 31: 
1091–1093.
 51. Choy, F. Y., and R. G. Davidson. 1980. Gaucher disease. III. Substrate 
specificity of glucocerebrosidase and the use of nonlabeled natural 
substrates for the investigation of patients. Am. J. Hum. Genet. 32: 
670–680.
 52. Motabar, O., E. Goldin, W. Leister, K. Liu, N. Southall, W. Huang, 
J. J. Marugan, E. Sidransky, and W. Zheng. 2012. A high throughput 
 at W
alaeus Library / BIN 299, on January 9, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2017/10/12/jlr.M079376.DC1
Supplemental Material can be found at:
Visualizing GBA in human skin: zymography versus ABP-labeling 2309
glucocerebrosidase assay using the natural substrate glucosylce-
ramide. Anal. Bioanal. Chem. 402: 731–739.
 53. Galis, Z. S., G. K. Sukhova, and P. Libby. 1995. Microscopic localiza-
tion of active proteases by in situ zymography: detection of matrix 
metalloproteinase activity in vascular tissue. FASEB J. 9: 974–980.
 54. Yan, S. J., and E. A. Blomme. 2003. In situ zymography: a molecular 
pathology technique to localize endogenous protease activity in tis-
sue sections. Vet. Pathol. 40: 227–236.
 55. Frederiks, W. M., and O. R. Mook. 2004. Metabolic mapping of pro-
teinase activity with emphasis on in situ zymography of gelatinases: 
review and protocols. J. Histochem. Cytochem. 52: 711–722.
 56. Patalay, R., C. Talbot, Y. Alexandrov, I. Munro, M. A. A. Neil, K. 
Konig, P. M. W. French, A. Chu, G. W. Stamp, and C. Dunsby. 2011. 
Quantification  of  cellular  autofluorescence  of  human  skin  using 
multiphoton tomography and fluorescence lifetime imaging in two 
spectral detection channels. Biomed. Opt. Express. 2: 3295–3308.
 57. König, K. 2008. Clinical multiphoton tomography. J. Biophotonics. 1: 
13–23.
 58. Collins, K. D. 1997. Charge density-dependent strength of hydration 
and biological structure. Biophys. J. 72: 65–76.
 59. Man, M. Q., T. K. Lin, J. L. Santiago, A. Celli, L. Zhong, Z. M. Huang, 
T. Roelandt, M. Hupe, J. P. Sundberg, K. A. Silva, et al. 2014. Basis 
for enhanced barrier function of pigmented skin. J. Invest. Dermatol. 
134: 2399–2407.
 60. Nemori, R., and T. Tachikawa. 1999. A review for in situ zymogra-
phy: method for localization of protease activities in a tissue. The 
Tissue Culture Engineering. 25: 29–32.
 61. Fabrega, S., P. Durand, P. Codogno, C. Bauvy, C. Delomenie, B. 
Henrissat, B. M. Martin, C. McKinney, E. I. Ginns, J. P. Mornon, 
et al. 2000. Human glucocerebrosidase: heterologous expression of 
active site mutants in murine null cells. Glycobiology. 10: 1217–1224.
 62. Aerts, J. M., S. Brul, W. E. Donker-Koopman, S. van Weely, G. J. 
Murray, J. A. Barranger, J. M. Tager, and A. W. Schram. 1986. 
Efficient routing of glucocerebrosidase to lysosomes requires 
complex oligosaccharide chain formation. Biochem. Biophys. Res. 
Commun. 141: 452–458.
 63. Van Weely, S., J. M. Aerts, M. B. Van Leeuwen, J. C. Heikoop, W. E. 
Donker-Koopman, J. A. Barranger, J. M. Tager, and A. W. Schram. 
1990. Function of oligosaccharide modification in glucocerebrosi-
dase, a membrane-associated lysosomal hydrolase. Eur. J. Biochem. 
191: 669–677.
 64. Ben Bdira, F., W. W. Kallemeijn, S. V. Oussoren, S. Scheij, B. 
Bleijlevens, B. I. Florea, C. van Roomen, R. Ottenhoff, M. van 
Kooten, M. T. C. Walvoort, et al. 2017. Stabilization of glucocer-
ebrosidase by active site occupancy. ACS Chem. Biol. 12: 1830–1841.
 65. Urban, D. J., W. Zheng, O. Goker-Alpan, A. Jadhav, M. E. Lamarca, 
J. Inglese, E. Sidransky, and C. P. Austin. 2008. Optimization and 
validation of two miniaturized glucocerebrosidase enzyme assays for 
high throughput screening. Comb. Chem. High Throughput Screen. 11: 
817–824.
 66. Uchida, Y., M. Hara, H. Nishio, E. Sidransky, S. Inoue, F. Otsuka, 
A. Suzuki, P. M. Elias, W. M. Holleran, and S. Hamanaka. 2000. 
Epidermal sphingomyelins are precursors for selected stratum cor-
neum ceramides. J. Lipid Res. 41: 2071–2082.
 67. Danso, M., W. Boiten, V. van Drongelen, K. Gmelig Meijling, G. 
Gooris, A. El Ghalbzouri, S. Absalah, R. Vreeken, S. Kezic, J. van 
Smeden, et al. 2017. Altered expression of epidermal lipid bio-syn-
thesis enzymes in atopic dermatitis skin is accompanied by changes 
in stratum corneum lipid composition. J. Dermatol. Sci. 88: 57–66.
 68. Sugiura, A., T. Nomura, A. Mizuno, and G. Imokawa. 2014. 
Reevaluation of the non-lesional dry skin in atopic dermatitis by 
acute barrier disruption: an abnormal permeability barrier homeo-
stasis with defective processing to generate ceramide. Arch. Dermatol. 
Res. 306: 427–440.
 69. Jin, K., Y. Higaki, Y. Takagi, K. Higuchi, Y. Yada, M. Kawashima, and 
G. Imokawa. 1994. Analysis of beta-glucocerebrosidase and cerami-
dase activities in atopic and aged dry skin. Acta Derm. Venereol. 74: 
337–340.
 70. Fluhr, J. W., and P. M. Elias. 2002. Stratum corneum pH: forma-
tion and function of the ‘acid mantle’. Exogenous Dermatology. 1: 
163–175.
 71. Abdul-Hammed, M., B. Breiden, G. Schwarzmann, and K. Sandhoff. 
2017. Lipids regulate the hydrolysis of membrane bound glucosyl-
ceramide by lysosomal beta-glucocerebrosidase. J. Lipid Res. 58: 
563–577.
 72. Schmid-Wendtner, M. H., and H. C. Korting. 2006. The pH of the 
skin surface and its impact on the barrier function. Skin Pharmacol. 
Physiol. 19: 296–302.
 73. Holleran, W. M., Y. Takagi, G. K. Menon, S. M. Jackson, J. M. Lee, 
K. R. Feingold, and P. M. Elias. 1994. Permeability barrier require-
ments regulate epidermal beta-glucocerebrosidase. J. Lipid Res. 35: 
905–912.
 at W
alaeus Library / BIN 299, on January 9, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2017/10/12/jlr.M079376.DC1
Supplemental Material can be found at:
